

**MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-
BMSIC/DRUGS/23-11 (RE-TENDER FOR RATE CONTRACT AND SUPPLY OF DRUGS FOR
DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 21st December 2023

Venue: BMSICL Conference Hall.

The **Financial Evaluation Committee Meeting for Tender No. BMSIC/DRUGS/23-11** was held on **21st December 2023** under the Chairmanship of **Managing Director, BMSICL**. The other committee members present in the meeting were:

1. Dr. Sunil Kumar Jha, Director in Chief, Health Department, GoB.
2. Sh. Shrawan Kumar, Internal Financial Advisor (IFA), of Health Department, GoB.
3. Najar Hussain, CGM (Supply Chain), BMSICL.
4. Sh. Ravindra Kumar, GM (Procurement), BMSICL.
5. Sh. Mrityunjay Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
6. Dr. Vidyapati Choudhary, Principal PMCH, Patna.
7. Sh. Ramendra Kumar, GM (Finance), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/23-11.
2. Tender floated date- 30/06/2023.
3. Last date of submission of online bids- 08/08/2023.

3. The Tender has been floated on e-proc2 Portal for total 07 (Seven) Drugs.

4. Total 06 (Six) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

S. No.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s Cadila Pharmaceuticals Limited	Ok	Received	Ok
2	M/s Coral Laboratories Ltd	Ok	Received	Ok
3	M/s Digital Vision	Ok	Received	Ok
4	M/s East African (India) Overseas	Ok	Received	Ok
5	M/s Pfizer Limited	Ok	Received	Ok
6	M/s Tanpal Pharmaceuticals	Ok	Received	Ok

5. The drug wise bid received status was as follows:

S.N.	Name of the Product	Participating Firms	No. of Bids
1	Biphasic Isophane Insulin Injection 40 IU/ml	M/s Cadila Pharmaceuticals Limited	1
2	Soluble Insulin Injection (Regular) 40IU/ml	M/s Cadila Pharmaceuticals Limited	1
3	Vitamin B Complex Capsule	M/s Coral Laboratories Ltd	4
		M/s East African (India) Overseas	
		M/s Pfizer Limited	
		M/s Tanpal Pharmaceuticals	
4	Haloperidol Injection 5mg/ml	No Bidder Participated	0

5	Clonazepam Tablet 0.5mg DT	M/s Digital Vision	2
		M/s Tanpal Pharmaceuticals	
6	Sulfasalazine Tablet 500mg	No Bidder Participated	0
7	Streptokinase Injection 1500000 IU	M/s Cadila Pharmaceuticals Limited	1

6. The summary of Bid received status was as follows:

1. No Bids received for **02** Drugs.
2. Single Bids received for **03** Drugs.
3. Multiple Bids received for **02** Drugs.

7. It was therefore unanimously decided to recommend for Re-tender of Drugs at NIT S.N.- 4 & 6 (**02 Drugs**) due to no bid condition and to evaluate the bids pertaining to only **03 drugs** (NIT S.N.- 1, 2 & 7) for which Single bid have been received as per the Notification of Finance Department, Govt. of Bihar vide Resolution No-7806 Dated-30-09-2016 (this being a retender) and **02 drugs** (NIT S.N.- 3 & 5) for which multiple bids have been received.

8. The Preliminary Evaluation of technical bids of the above-mentioned bidding firms was done by the assigned team including Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the website of BMSICL and Claims/objections were invited vide notice no. 5128 dated 21.09.2023.

9. After comparison of the clarification received from the bidders in the light of that notice and close examination of the documents submitted by the bidding firms, the Drug wise technical evaluation findings by TEC in its meeting dated 06.10.2023 were recorded as follows:

S.N.	NIT S.N.	Name of the Product	Participating Firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	1	Biphasic Isophane Insulin Injection 40 IU/ml	M/s Cadila Pharmaceuticals Limited	Qualified	Ok
2	2	Soluble Insulin Injection (Regular) 40IU/ml	M/s Cadila Pharmaceuticals Limited	Qualified	Ok
3	3	Vitamin B Complex Capsule	M/s Coral Laboratories Ltd	Qualified	Ok
			M/s East African (India) Overseas	Qualified	Ok
			M/s Pfizer Limited	Qualified	Ok
			M/s Tanpal Pharmaceuticals	Disqualified	Income tax return as per clause 3(m), Audited Balance Sheet & Profit and loss statement as per Clause 3(l), Valid Pollution Control Clearance Certificate as per Clause 3(f) & MPCC as per

					Clause 3(k) not submitted.
			M/s Digital Vision	Qualified	Ok
4	5	Clonazepam Tablet 0.5mg DT	M/s Tanpal Pharmaceuticals	Disqualified	Income tax return as per clause 3(m), Audited Balance Sheet & Profit and loss statement as per Clause 3(l), Product approval, Market Standing Certificate and Valid Pollution Control Clearance Certificate as per Clause 3(f) & MPCC as per Clause 3(k) not submitted.
5	7	Streptokinase Injection 1500000 IU	M/s Cadila Pharmaceuticals Limited	Qualified	Ok

10. As per the above comparative chart Five (05) bidders namely, M/s Cadila Pharmaceuticals Limited, M/s Coral Laboratories Ltd., M/s Digital Vision, M/s East African (India) Overseas & M/s Pfizer Limited were found technically qualified as mentioned above.

11. One (01) firm i.e., M/s Tanpal Pharmaceuticals was found technically disqualified.

12. The manufacturing unit of the Four (04) firms namely, M/s Cadila Pharmaceuticals Limited, M/s Coral Laboratories Ltd., M/s Digital Vision & M/s East African (India) Overseas were inspected previously and/or are having valid rate contract with BMSICL. It was therefore unanimously decided by TEC in its meeting dated 06.10.2023 to recommend for factory inspection of remaining (01) one firm i.e., M/s Pfizer Limited.

13. The factory inspection of above mentioned (01) one firm has been conducted by the team of Drug Inspectors. After perusal of the Factory Inspection report, the product wise technical evaluation findings by TEC in its meeting dated 05.12.2023 were recorded as follows:

S.N.	NIT S.N.	Name of the Product	Participating Firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	1	Biphasic Isophane Insulin Injection 40 IU/ml	M/s Cadila Pharmaceuticals Limited	Qualified	Ok
2	2	Soluble Insulin Injection (Regular) 40IU/ml	M/s Cadila Pharmaceuticals Limited	Qualified	Ok

3	3	Vitamin B Complex Capsule	M/s Coral Laboratories Ltd	Qualified	Ok
			M/s East African (India) Overseas	Qualified	Ok
			M/s Pfizer Limited	Qualified for Puducherry Unit	Disqualified for Aurangabad Unit (The unit doesn't have three (3) year old manufacturing and marketing experience of the quoted product)
			M/s Tanpal Pharmaceuticals	Disqualified	Income tax return as per clause 3(m), Audited Balance Sheet & Profit and loss statement as per Clause 3(l), Valid Pollution Control Clearance Certificate as per Clause 3(f) & MPCC as per Clause 3(k) not submitted.
4	5	Clonazepam Tablet 0.5mg DT	M/s Digital Vision	Qualified	Ok
			M/s Tanpal Pharmaceuticals	Disqualified	Income tax return as per clause 3(m), Audited Balance Sheet & Profit and loss statement as per Clause 3(l), Product approval, Market Standing Certificate and Valid Pollution Control Clearance Certificate as per Clause 3(f) & MPCC as per Clause 3(k) not submitted.
5	7	Streptokinase Injection 1500000 IU	M/s Cadila Pharmaceuticals Limited	Qualified	Ok

14. As per the above comparative chart Five (05) bidders namely, M/s Cadila Pharmaceuticals Limited, M/s Coral Laboratories Ltd., M/s Digital Vision, M/s East African (India) Overseas & Puducherry unit of M/s Pfizer Limited were found technically qualified as mentioned above.

15. One (01) firm i.e., M/s Tanpal Pharmaceuticals and Aurangabad unit of M/s Pfizer Limited was found technically disqualified.

16. It was therefore unanimously recommend findings by TEC in its meeting dated 05.12.2023 to proceed further for the Opening of Financial Bids for Vitamin B Complex Capsule (NIT Sl. No. 3) for which multiple bidders have been qualified technically. It was also unanimously recommend for proceed further for opening of financial bids for 04 drugs for which single bidder has qualified technically, in accordance to the provision contained in the Notification No-7806, Dated 30-09-2016 of Finance Department, Govt. of Bihar, as this is Re-Tender.

17. Accordingly, the financial bids of technically qualified bidders were opened today on e-proc2 Portal, in which the following result has been observed: -

S.N.	NIT S.N.	Name of the Product	Participating Firms	Quoted Rate (Rs.) for Each Unit (per Tablet/per Capsule/per Vial/per ampoule} (Excluding GST)	Bid Ranking
1	1	Biphasic Isophane Insulin Injection 40 IU/ml	M/s Cadila Pharmaceuticals Limited	63	NA
2	2	Soluble Insulin Injection (Regular) 40IU/ml	M/s Cadila Pharmaceuticals Limited	62.8	NA
3	3	Vitamin B Complex Capsule	M/s East African (India) Overseas	0.79	L1
			M/s Pfizer Limited	0.8	L2
			M/s Coral Laboratories Ltd	1.5	L3
4	5	Clonazepam Tablet 0.5mg DT	M/s Digital Vision	0.99	NA
5	7	Streptokinase Injection 1500000 IU	M/s Cadila Pharmaceuticals Limited	750	NA

18. Since this tender is a retender, it was unanimously decided to ask the bidders for the **04 drugs** (NIT S.N.- 1, 2, 5 & 7) under single bid condition to justify their quoted price vis-à-vis other procurement agencies across the country and to find out the prevailing market rate (Authorized dealer price, Carrying & Forwarding Agent Price & Sales depot price) of the corresponding manufacturer through the State Drug Regulatory Authority, so that the matter could be decided by the board of Directors of BMSICL as per the provisions contained in the notification no. 7806 dated 30/09/2016 of Finance Department, Govt. of Bihar and to issue the LoI for Drugs at NIT S.N.- 3 (**Vitamin B Complex Capsule**) as per provisions of splitting contained in the tender clause 19 (a) of the Tender Document.

19. The meeting thus concluded with a vote of thanks.

Sd/-
(**Ramendra Kumar**)
GM (Finance), BMSICL, Patna

Sd/-
(**Dr. Vidyapati Choudhary**)
Principal PMCH, Patna

Sd/-
(**Mrityunjay Kumar**)
Administrative Officer-cum-I/C Procurement,
SHSB.

Sd/-
(**Ravindra Kumar**)
GM (Procurement), BMSICL, Patna

Sd/-
(**Najar Hussain**)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(**Shrawan Kumar**)
Internal Financial Advisor, Health Dept., Govt. of Bihar.

Sd/-
(**Dr. Sunil Kumar Jha**)
Director in Chief, Health Dept., Govt. of Bihar.

Sd/-
(**Dinesh Kumar**)
Managing Director, BMSICL